Help Develop the First Mono Vaccine

News

About the trial

The Moderna Epstein-Barr Virus (EBV) Vaccine trial is enrolling 18-21 year olds to evaluate an investigational vaccine aimed at preventing this viral infection.

$100 compensation for each in-person visit, $50 per scheduled phone check-in.
All study-related care, tests, and procedures are provided at no cost to you.
Participants are randomly assigned to receive the investigational vaccine or placebo.

Apply To a Trial

Apply for this Trial & take the first step towards better care for yourself today.

"*" indicates required fields

Your Name*

Email*

Date of Birth

Phone Number*

Address*

How did you hear about us?*

I am a returning patient.

I saw HRHR on social media.

I found HRHR on the internet.

Someone referred me.

I received an email.

I received a postcard.

Other

This field is hidden when viewing the form

Trial Applying To

CAPTCHA

This field is for validation purposes and should be left unchanged.

Why the Epstein-Barr Virus (EBV) Vaccine Matters

The Epstein-Barr Virus (EBV) is one of the most common viruses in the world, spreading through close contact like kissing or sharing drinks. By age 24, about 90% of people have been exposed. While many infections go unnoticed, EBV is the leading cause of mono, which can lead to extreme fatigue, fever, sore throat, and swollen glands—it’s a lifelong infection that stays in your body permanently once contracted. While some people may never experience symptoms, the virus can still pose serious long-term health risks.

Currently, there is no approved vaccine for EBV, but this study aims to change that. Participants will play a vital role in advancing research while receiving study-related medical care at no cost.

How You Can Help

By participating in this clinical trial, you have the unique opportunity to be part of groundbreaking research that could help stop EBV infections before they start. The more we understand, the closer we get to developing a safe, effective vaccine to protect future generations from this lifelong virus.

This investigational vaccine does not contain the live virus, so it is not possible to get EBV or mono from the vaccine. Instead, the study vaccine uses mRNA technology—the same type of approach used in other widely used vaccines—to help the immune system recognize and fight the virus.

back

Latest News